Response to ragweed allergen provocation in the Red Maple Trials Allergen Challenge TheatreTM
Poster Feb 24, 2015
Suzanne Kelly, PHD;Jacob Karsh, MDCM, FRCPC; Jimmy Yang, MBA; William H. Yang, MD, FRCPC, FAAAAI
Rationale: Allergen challenge chambers expose allergen-sensitive subjects to a predetermined concentration of allergen in a closed, controlled environment and provide a mechanism to induce clinical symptoms and measure the effect of medication.
Methods: We evaluated the response of ragweed-allergic subjects to two ragweed challenges in the Red Maple Trials Allergen Challenge Theatre. A provincial Ethics Board approved the study. After signing informed consent, patients with a history of ragweed allergy, not on allergy medications and with a positive skin prick test to ragweed antigen (> 3 mm) were exposed to ragweed pollen in a 3-hour priming session. Total nasal (TNSS), ocular and respiratory symptom scores (TRSS) were recorded at baseline and every 30 minutes during the challenge. Those with a TNSS > were then selected for 2 further 4-hour challenges.
Results: 48/76 subjects evaluated underwent the priming challenge. Thirty-three subjects achieving a peak TNSS ≥5 were selected for two subsequent 4-hour challenges. Baseline TNSS (mean± SD) was 1.70 ±1.34 and 2.53±1.76 in challenges 1 and 2, respectively. Baseline TRSS values were 2.00± 1.66 and 3.60±2.69 respectively. Symptom scores reached a plateau by 120 minutes and remained steady for the remainder of the 240-minute exposure period. Plateau TNSS was 6.28±0.20 for Challenge 1and 6.19±0.24 for Challenge 2. Similarly, TRSS values were 9.10±0.20 and 9.11± 0.33, respectively.
Conclusions: The Red Maple Trials allergen exposure theatre demonstrated the capacity to induce symptoms of appropriate intensity upon allergen challenge. Our chamber with a seating capacity of 100 places has the ability to evaluate large test groups at a time.
Treatment Options for Chronic Parvovirus Viremia in Pediatric Heart Transplant Patients in a Tertiary Care CenterPoster
This abstract discusses three cases of pediatric heart transplant patients who suffered from parvovirus (B19) infection. Of these patients, two ( B & C) responded well to standard intravenous Ig therapy. Patient A however, did not respond to standard treatment and was begun on subcutaneous Ig, which effectively diminished his viral load. Thus, subcutaneous Ig infusions might serve as a second line treatment for transplant patients with parvovirus who do not respond well to the standard approach.READ MORE
T-helper cell phenotype expression in cutaneous lesions of angioimmunoblastic T-cell lymphomaPoster
Angioimmunoblastic T-cell lymphoma (AITL) is a common type of peripheral T-cell lymphoma. AITL can be missed until lymphadenopathy develops in patients initially presenting with skin lesions, as skin biopsy may lack conclusive findings. Our case highlights the extranodal presentation of AITL with cutaneous lesions displaying the TFH phenotype.READ MORE
The Utility of Pediatric Asthma Severity Scores in Disposition Decisions for Status AsthmaticusPoster
We aimed to determine if the Pediatric Asthma Severity Score (PASS) predicts a patient's appropriate level of care in the inpatient setting, with special attention to patients who required rapid transfer to another level of care after initial disposition and/or hospital readmission.READ MORE